Mike Frank is the CEO of Revive Therapeutics (CNSX: RVV), and Dr. Kelly Mckee is their chief scientific advisor. In this podcast, we discuss Bucillamine, a drug that has been used safely for over 30 years in Japan and South Korea to treat rheumatic arthritis that is currently in phase 3 clinical trials (FDA approved) to treat COVID. Bucillamine has a fascinating mechanism of action because it acts very similarly to N-acetylcysteine (NAC) by restoring glutathione levels. While it's currently being studied to treat COVID, we hypothesize that it may also work prophylactically and as a treatment for long COVID.